New member: Glaxo Smith Kline
Find out how Glaxo Smith Kline (GSK), the latest pharmaceutical cluster to enter into our ecosystem, is contributing to the oncology field.
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 278 entries.
Find out how Glaxo Smith Kline (GSK), the latest pharmaceutical cluster to enter into our ecosystem, is contributing to the oncology field.
Our funding support: up to €60 000 per SME
DIGI-B-CUBE Open Call – Innovation vouchers to support the SMEs
Find out why a company specialising in seafood and marine ingredients has become a member of an oncology cluster.
Oslo Cancer Cluster Innovation Park opened in May 2015.
The Innovation Park brings together the oncology-value chain from basic research to industry within the Oslo-area.
Our vision is to create Europe's leading environment for education, research and industry within oncology, shortening the development time of new cancer treatments.